This website provides educational information about medicines and active ingredients. It does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Pill Identifier

JKI 11 Pink Oval Pill Identifier

Quick summary: The pink oval pill with imprint JKI 11 is identified in the source content as Xeljanz XR, containing 11 mg of tofacitinib. It is described as a medicine used for certain autoimmune...

Educational content Use this article as a starting point for understanding the topic.
Check with a professional Ask a doctor or pharmacist before changing any medicine.
Safety first Side effects, interactions and risks depend on each person.
Medical disclaimer

This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.

Quick summary: The pink oval pill with imprint JKI 11 is identified in the source content as Xeljanz XR, containing 11 mg of tofacitinib. It is described as a medicine used for certain autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Always confirm any pill by its imprint, shape, color, and packaging, and check the official leaflet or a pharmacist if anything does not match.

Medical disclaimer: This page is for general identification and education only. It is not a diagnosis, and it does not replace advice from a licensed healthcare professional. If a pill is unknown, damaged, or may have been taken by mistake, contact a pharmacist, poison center, or emergency services right away.

What is the JKI 11 pill?

The JKI 11 pill is described in the source content as a pink oval 8 mm tablet associated with Xeljanz XR. It contains 11 mg of tofacitinib, a medicine used for certain autoimmune disorders.

Because pill appearance can vary by manufacturer, packaging, and region, the imprint alone should not be the only way to identify a tablet. Matching the imprint, color, shape, and strength is important.

What is Xeljanz XR used for?

According to the source content, Xeljanz XR is indicated for:

  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Ulcerative colitis

The article source also notes that it may be used when other treatments have failed or are not suitable. For the exact approved use of any medicine, readers should check the official prescribing information or ask a healthcare professional.

How does it work?

Xeljanz XR is described as a Janus kinase (JAK) inhibitor. In the source content, it works by interfering with pathways involved in inflammation, which may help reduce symptoms linked to autoimmune disease.

This mechanism is presented as helping with inflammation, swelling, pain, and stiffness. Individual response can vary, so treatment decisions should always be guided by a clinician.

Dosage form and strength

The source content identifies this product as an extended-release tablet with a strength of 11 mg.

Extended-release tablets are designed to release medicine over time. Do not assume a tablet is safe to split, crush, or chew unless the official instructions say so.

Identifier Details from source content
Imprint JKI 11
Color Pink
Shape Oval
Size 8 mm
Strength 11 mg
Form Extended-release tablet

Warnings and precautions

The source content highlights several important warnings for Xeljanz XR:

  • Increased risk of serious infections
  • Potential for blood clots
  • Need for monitoring liver enzyme levels

Because of these risks, the article source emphasizes regular monitoring by a healthcare provider. Any new or worsening symptoms should be discussed promptly with a clinician.

Possible adverse reactions

The source content lists the following possible side effects:

  • Headache
  • Nausea
  • Upper respiratory infections

It also notes more serious reactions that may include:

  • Serious infections
  • Blood clots
  • Liver problems

If a symptom seems severe, unusual, or rapidly worsening, seek medical advice promptly.

Who may need closer monitoring?

The source content says administration may vary for certain groups, including:

  • Older adults
  • People with liver disease
  • People with a history of infections

These groups may need closer follow-up or additional screening before treatment, depending on the prescribing clinician’s judgment.

How to verify a pill safely

If you are trying to identify a tablet marked JKI 11, compare all visible details:

  • Imprint
  • Color
  • Shape
  • Approximate size
  • Packaging or prescription label

If the pill does not match the prescription label, or if the tablet is loose, damaged, or unlabelled, ask a pharmacist to verify it before use.

Frequently asked questions

▸ What is a pink oval pill with JKI 11 on it?

The source content identifies it as Xeljanz XR containing 11 mg of tofacitinib.

▸ What conditions is Xeljanz XR used for?

The source content lists rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

▸ Is the JKI 11 pill an extended-release tablet?

Yes. The source content describes it as an extended-release tablet.

▸ What are the main safety concerns mentioned?

The source content mentions serious infections, blood clots, and liver enzyme monitoring.

▸ What should I do if I am not sure about a pill?

Do not take it until it has been verified by a pharmacist or other qualified healthcare professional.

Safety reminder: If a pill is unknown or may have been taken accidentally, get immediate help from a pharmacist, poison center, or emergency service. For any medicine questions, use the official patient leaflet and your prescriber’s instructions.

Editorial note Active Ingredients Online Editorial Team This article is prepared as educational medicine information for general readers. It is written to support understanding of active ingredients, medicine uses, possible side effects, precautions and safety-related questions.
Published: January 21, 2025 Updated: June 5, 2026 Educational content

Medical disclaimer

This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.

Sources and verification

The following sources or official references are listed to support verification of the medicine information discussed in this article.

Final note

Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.

See also...
Ask a Doctor Online medical questions